The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KURA | +18.82% | -70.68% | -21.74% | -42% |
| S&P | +20.12% | +68.19% | +10.95% | +232% |
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $17.34M | -67.8% |
| Gross Profit | $16.88M | -68.6% |
| Gross Margin | 97.35% | -2.3% |
| Market Cap | $904.11M | 33.5% |
| Market Cap / Employee | $3.48M | 0.0% |
| Employees | 260 | 35.4% |
| Net Income | -$80,999.00K | -321.5% |
| EBITDA | -$85,865.00K | -285.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $149.10M | -33.6% |
| Accounts Receivable | $8.80M | 0.0% |
| Inventory | 0.4 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $19.18M | 58.4% |
| Short Term Debt | $1.28M | -71.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -31.33% | -8.0% |
| Return On Invested Capital | -29.85% | -2.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $114.95M | -57.2% |
| Operating Free Cash Flow | $117.27M | -56.4% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.25 | 1.28 | 2.51 | 3.73 | 133.27% |
| Price to Sales | 8.49 | 6.07 | 7.46 | 13.56 | -3.75% |
| Price to Tangible Book Value | 1.25 | 1.28 | 2.51 | 3.73 | 133.27% |
| Price to Free Cash Flow TTM | 5.67 | 5.22 | 4.11 | 9.33 | - |
| Enterprise Value to EBITDA | 0.96 | 1.46 | -3.07 | -3.12 | 44.26% |
| Free Cash Flow Yield | 17.6% | 19.2% | 24.3% | 10.7% | - |
| Return on Equity | -41.8% | -51.1% | -65.1% | -94.8% | 120.97% |
| Total Debt | $19.35M | $19.47M | $19.47M | $20.46M | 23.28% |
No podcast episodes available.
KURA earnings call for the period ending September 30, 2021.
KURA earnings call for the period ending June 30, 2021.
KURA earnings call for the period ending March 31, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
